RET rearrangements in non–small cell lung cancer (NSCLC) appear to be associated with a high risk for brain metastases. They occur in approximately 25% of patients with RET-positive NSCLC, although in the ARROW trial, approximately 50% of the patients with RET-altered NSCLC were found to have developed brain metastases. In the LIBRETTO-01 study, 36% of patients had brain metastases. The lifetime prevalence of brain metastasis in stage IV NSCLC has been reported to be 46%.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: John C. Leighton Jr. Skill Checkup: A 53-Year-Old Woman With Dry Cough and a Lung Lesion - Medscape - Sep 01, 2022.